Breaking Finance News

Epizyme Inc (NDAQ:EPZM) stock price target increased to $23.00, issued a report today by Jefferies & Co

Yesterday Epizyme Inc (NDAQ:EPZM) traded 3.46% higher at $18.45. The company’s 50-day moving average is $15.50 and its 200-day moving average is $15.25. The last closing price is up 30.64% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 406,097 shares of the stock traded hands, down from an average trading volume of 582,080

In a report released on Wednesday September 20, 2017 Jefferies & Co increased the stock price target of Epizyme Inc (NDAQ:EPZM) to $23.00 indicating a possible upside of 0.25%.

Previously on 06/16/2017, Citigroup reported on Epizyme Inc (NDAQ:EPZM) increased the target price from $20.00 to $22.00. At the time, this indicated a possible upside of 0.61%.

See Chart Below

Epizyme Inc (NDAQ:EPZM)

Epizyme Inc has a 52 week low of $8.38 and a 52 week high of $20.00 The company’s market cap is currently $0.

In addition to Jefferies & Co reporting its stock price target, a total of 8 brokers have issued a report on the company. The average stock price target is $24.50 with 3 brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Epizyme Inc (NDAQ:EPZM)

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.